Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RAfWqAZ-UTw0gNnIXkqQG2l6pPL7o0NgFGMyA2JkH3g7k#assertion>. }
Showing items 1 to 60 of
60
with 100 items per page.
- subject C0011777 "dexamethasone" assertion.
- subject C4726677 "remdesivir" assertion.
- subject C5203670 "COVID-19" assertion.
- subject C0087111 "therapeutic" assertion.
- subject C0020336 "hydroxychloroquine" assertion.
- subject C3245505 "potential" assertion.
- subject C0013227 "drugs" assertion.
- subject C3687832 "drugs" assertion.
- subject C0008269 "chloroquine" assertion.
- object C0332281 "associated" assertion.
- subject C1947944 "use" assertion.
- subject C1704787 "certain" assertion.
- subject C3811910 "combination" assertion.
- subject C1947911 "combination" assertion.
- subject C0205195 "combination" assertion.
- subject C3540710 "antibiotics" assertion.
- subject C3540709 "antibiotics" assertion.
- subject C3540708 "antibiotics" assertion.
- subject C3540707 "antibiotics" assertion.
- subject C3540706 "antibiotics" assertion.
- subject C3540705 "antibiotics" assertion.
- subject C3540704 "antibiotics" assertion.
- subject C0003237 "antibiotics" assertion.
- subject C0003232 "antibiotics" assertion.
- object C3272565 "clinical" assertion.
- object C0205210 "clinical" assertion.
- subject C0812732 "azithromycin" assertion.
- subject C0052796 "azithromycin" assertion.
- subject C0001617 "corticosteroids" assertion.
- subject C1547427 "therapeutic" assertion.
- subject C0723712 "therapeutic" assertion.
- subject C1609165 "tocilizumab" assertion.
- subject C1138226 "favipiravir" assertion.
- subject C3540727 "corticosteroids" assertion.
- subject C3540726 "corticosteroids" assertion.
- subject C3540725 "corticosteroids" assertion.
- subject C3539185 "corticosteroids" assertion.
- subject C4553887 "biologics" assertion.
- subject C4551445 "label" assertion.
- subject C4522130 "label" assertion.
- subject C3470573 "led" assertion.
- subject C2827499 "label" assertion.
- subject C1708698 "led" assertion.
- subject C1705425 "label" assertion.
- subject C1522485 "label" assertion.
- subject C0674432 "lopinavir" assertion.
- subject C0292818 "ritonavir" assertion.
- subject C0205423 "certain" assertion.
- subject C0181496 "label" assertion.
- subject C0035366 "retroviral" assertion.
- subject C0005515 "biologics" assertion.
- subject C0003404 "antiparasitics" assertion.
- predicate select?q=TRIPLE_UID:a5s1weub-TRIPLE-ABSTRACT-3 "remain" assertion.
- object C1705413 "adverse events" assertion.
- object C0877248 "adverse events" assertion.
- triple label "Although the therapeutic potential of certain repurposed drugs has led to certain repurposed drugs 's off - label use against COVID-19 , such as anti - retroviral drugs ( remdesivir , favipiravir , and lopinavir - ritonavir combination ) , biologics ( tocilizumab ) , antibiotics ( azithromycin ) , antiparasitics ( chloroquine and hydroxychloroquine ) , and corticosteroids ( dexamethasone ) remains the associated clinical neuropsychiatric adverse events" assertion.
- sentence label "Although the therapeutic potential of certain repurposed drugs has led to certain repurposed drugs's off-label use against COVID-19, such as anti-retroviral drugs (remdesivir, favipiravir, and lopinavir-ritonavir combination), biologics (tocilizumab), antibiotics (azithromycin), antiparasitics (chloroquine and hydroxychloroquine), and corticosteroids (dexamethasone), unfortunately, the associated clinical neuropsychiatric adverse events remains a critical issue." assertion.
- version value "1" assertion.
- assertion wasGeneratedBy "S&T TWOC project version 1" assertion.
- Triple-UID select?q=TRIPLE_UID:a5s1weub-TRIPLE-ABSTRACT-3 "a5s1weub-TRIPLE-ABSTRACT-3" assertion.